Wednesday, November 11, 2026
ExploreSearch
Via News
Via News Knowledge File

Merck & Co., Inc.

organization80% conf.·synced Nov 11, 2026

Pharmaceutical company based in Rahway, NJ, known as MSD outside US and Canada

60
sourced metrics
676
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Market Cap
365264761006USD
Nov 10, 2026reference only
Stock Return Ytd
39.1%
Nov 10, 2026reference only
Stock Price
148.05USD
Nov 10, 2026reference only
Price 52 Week Low
90.95USD
Nov 10, 2026reference only
Price 52 Week High
156.45USD
Nov 10, 2026reference only
Shares Outstanding
2467171638.0shares
Jul 31, 2026reference only
Rd Expense
9741000000.0USD
Jun 30, 2026reference only
Stockholders Equity
41933000000.0USD
Jun 30, 2026reference only
Net Income
-1335000000.0USD
Jun 30, 2026reference only
Total Assets
129802000000.0USD
Jun 30, 2026reference only
Cost Of Revenue
4395000000.0USD
Jun 30, 2026reference only
Cash
6849000000.0USD
Jun 30, 2026reference only
Eps
-0.54USD_per_share
Jun 30, 2026reference only
Revenue
16607000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
3918000000.0USD
Mar 31, 2026reference only
Capex
991000000.0USD
Mar 31, 2026reference only

Stated objectives

Accelerate non-Keytruda pharmaceutical revenue growth from 3% in FY2024 to 12%+ by FY2027

source
target: 12%+ YoY growth by 2027-01-01 00:00:00stated

Enroll approximately 675 patients in KANDLELIT-007 Phase 3 trial

source
target: 675 patients stated

Evaluate progression-free survival as primary endpoint in PD-L1 TPS ≥1% patients in KANDLELIT-007

source
stated

Evaluate secondary endpoints including PFS in all patients, overall survival, objective response rate, duration of response, and safety in KANDLELIT-007

source
stated

Submit regulatory filings worldwide for KEYTRUDA + Padcev combination in muscle-invasive bladder cancer based on KEYNOTE-B15/EV-304 results

source
stated

Initiate second Merck-sponsored pivotal trial of zanzalintinib and belzutifan in RCC

source
stated

Full-year sales forecast

source
target: $64.5 billion to $65 billion by 2025-12-31 00:00:00stated

Full-year EPS forecast

source
target: $8.93 to $8.98 by 2025-12-31 00:00:00stated

Improving outcomes and addressing significant unmet needs for patients with hematologic neoplasms and malignancies

source
stated

Become the premier research-intensive biopharmaceutical company in the world

source
stated

Relationship graph · 676 connections

Developed by
275
Competes with
67
Employs
46
acquired by
42
Partnered with
42
regulates
29
headquartered in
29
Covered by
28
headquartered in
Rahway, New Jersey
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com